Authors:
BONN R
BOKENS H
HAMMES W
TRENK D
SEIBERLING M
JAHNCHEN E
Citation: R. Bonn et al., PHARMACOKINETICS AND DOSE PROPORTIONALITY OF SP W-4853, THE MAIN METABOLITE OF SP/W-5186 A NEW ORGANIC NITRATE/, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 627-627
Authors:
TRENK D
KOHLER H
DILGER K
STENGELE E
JAHNCHEN E
Citation: D. Trenk et al., QUANTITATIVE-ANALYSIS OF THE CONTRIBUTION OF THE METABOLITE ISOSORBIDE-5-MONONITRATE TO THE HEMODYNAMIC EFFECTIVENESS OF ISOSORBIDE DINITRATE, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 629-629
Authors:
TRENK D
HINDER M
FUNG E
STENGELE E
BONN R
JAHNCHEN E
Citation: D. Trenk et al., HEMODYNAMIC-EFFECTS OF THE NEW NO-RELEASING COMPOUND SP W-5186 IN HEALTHY-VOLUNTEERS - COMPARISON WITH ISOSORBIDE-5-MONONITRATE/, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 658-658
Citation: D. Trenk et al., ARE HEMODYNAMIC SURROGATE PARAMETERS OF NO-RELEASING DRUGS IN HEALTHY-VOLUNTEERS SUITABLE PREDICTORS OF THE ANTIISCHEMIC AND ANTIANGINAL EFFECTS IN PATIENTS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 22-22
Authors:
KOHLER H
TRENK D
DILGER K
STENGELE E
JAHNCHEN E
Citation: H. Kohler et al., MAJOR CONTRIBUTION OF THE FORMED METABOLITE ISOSORBIDE-5-MONONITRATE TO THE HEMODYNAMIC-EFFECTS OF ISOSORBIDE DINITRATE 120 MG, Clinical pharmacology and therapeutics, 63(2), 1998, p.
Authors:
RUSSMANN S
GOHLKEBARWOLF C
JAHNCHEN E
TRENK D
ROSKAMM H
Citation: S. Russmann et al., AGE-DEPENDENT DIFFERENCES IN THE ANTICOAGULANT EFFECT OF PHENPROCOUMON IN PATIENTS AFTER HEART-VALVE SURGERY, European Journal of Clinical Pharmacology, 52(1), 1997, pp. 31-35
Authors:
STENGELE E
DILGER K
WINKELMANN B
SCHULZ W
LOFFLER K
JAHNCHEN E
TRENK D
ROSKAMM H
Citation: E. Stengele et al., ANTIISCHEMIC EFFECTS OF CORMIN FOLLOWING INFUSION FOR 24 HOURS, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 422-422
Authors:
TRENK D
STENGELE E
LOFFLER K
ROSKAMM H
JAHNCHEN E
Citation: D. Trenk et al., ASSESSMENT OF HEMODYNAMIC SURROGATE PARAMETERS OF NO-DONORS IN HEALTHY-VOLUNTEERS - PREDICTORS OF THE ANTIISCHEMIC AND ANTIANGINAL EFFECTS IN PATIENTS WITH CORONARY HEART-DISEASE, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 423-423
Authors:
TRENK D
WALCHER P
WEEGER R
LOFFLER K
JAHNCHEN E
Citation: D. Trenk et al., DETERMINATION OF THE DOSE-RESPONSE RELATIONSHIPS OF THE HEMODYNAMIC-EFFECTS OF THE NOVEL SYDNONIMINE DERIVATIVE PIRSIDOMINE, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 435-435
Authors:
STENGELE E
HINDER M
TRENK D
MULLERPELTZER H
EICHELBAUM M
JAHNCHEN E
Citation: E. Stengele et al., NONINVASIVE DETERMINATION OF CARDIODEPRESSANT EFFECTS OF PROPAFENONE BY IMPEDANCE CARDIOGRAPHY, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 484-484
Authors:
BRESLIN E
POSVAR E
NEUB M
TRENK D
JAHNCHEN E
Citation: E. Breslin et al., A PHARMACODYNAMIC AND PHARMACOKINETIC COMPARISON OF INTRAVENOUS QUINAPRILAT AND ORAL QUINAPRIL, Journal of clinical pharmacology, 36(5), 1996, pp. 414-421
Authors:
STENGELE E
WINKLER F
TRENK D
JAHNCHEN E
PETERSEN J
ROSKAMM H
Citation: E. Stengele et al., DIGITAL PULSE PLETHYSMOGRAPHY AS A NONINVASIVE METHOD FOR PREDICTING DRUG-INDUCED CHANGES IN LEFT-VENTRICULAR PRELOAD, European Journal of Clinical Pharmacology, 50(4), 1996, pp. 279-282
Authors:
TRENK D
PFEFFERLE B
JONSSON UE
JAHNCHEN E
Citation: D. Trenk et al., DOSE RANGE STUDY OF THE HEMODYNAMIC-EFFECTS OF REPEATED ORAL DOSES OF30, 60 AND 120 MG OF ISOSORBIDE-5-MONONITRATE IN COMPARISON WITH PLACEBO, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 10-10
Authors:
TRENK D
DILGER K
STENGELE E
LOGEMANN C
JAHNCHEN E
Citation: D. Trenk et al., TIME PROFILE OF ACE-ACTIVITY IN PLASMA FOLLOWING IV-BOLUS DOSE OR IV-INFUSION OF THE ACE-INHIBITOR QUINAPRILAT, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 43-43
Authors:
STENGELE E
RUF G
JAHNCHEN E
TRENK D
LOFFLER K
SCHULZ W
ROSKAMM H
Citation: E. Stengele et al., SHORT-TERM HEMODYNAMIC, ANTIISCHEMIC, AND ANTIANGINAL EFFECTS OF PIRSIDOMINE, A NEW SYDNONIMINE, The American journal of cardiology, 77(11), 1996, pp. 937-941
Authors:
DELLAPASCHOA OE
LUCKOW V
TRENK D
JAHNCHEN E
SANTOS SRCJ
Citation: Oe. Dellapaschoa et al., PROLONGATION OF THE PQ INTERVAL AS A MEASURE OF THERAPEUTIC INEQUIVALENCE BETWEEN 2 FORMULATIONS OF DILTIAZEM, European Journal of Clinical Pharmacology, 48(1), 1995, pp. 45-49
Citation: E. Jahnchen et al., PHARMACOKINETICS OF THE CLASS-I ANTIARRHYTHMIC DRUG DIPRAFENONE IN POOR METABOLIZERS OF SPARTEIN DEBRISOQUINE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 151-151
Citation: D. Trenk et al., BETA-ADRENOCEPTOR BLOCKING ACTIVITY OF THE ENANTIOMERS OF DIPRAFENONEIN MAN, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 167-167
Citation: G. Ruf et al., DETERMINATION OF THE ANTIISCHEMIC ACTIVITY OF NEBIVOLOL IN COMPARISONWITH ATENOLOL, International journal of cardiology, 43(3), 1994, pp. 279-285
Authors:
RUF G
GERA S
LUUS HG
TRENK D
DELAREY N
LOFFLER K
SCHULTZ W
JAHNCHEN E
Citation: G. Ruf et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF RAMIPRIL AND PIRETANIDE ADMINISTERED ALONE AND IN COMBINATION, European Journal of Clinical Pharmacology, 46(6), 1994, pp. 545-550
Citation: D. Vogt et al., PHARMACOKINETICS AND HEMODYNAMIC-EFFECTS OF ISDN FOLLOWING DIFFERENT DOSAGE FORMS AND ROUTES OF ADMINISTRATION, European Journal of Clinical Pharmacology, 46(4), 1994, pp. 319-324
Authors:
KOVARIK JM
MUELLER EA
GABER M
JOHNSTON A
JAHNCHEN E
Citation: Jm. Kovarik et al., PHARMACOKINETICS OF CYCLOSPORINE AND STEADY-STATE ASPIRIN DURING COADMINISTRATION, Journal of clinical pharmacology, 33(6), 1993, pp. 513-521
Authors:
BUSCHMANN M
WIEGAND A
SCHNELLBACHER K
BONN R
REHE A
TRENK D
JAHNCHEN E
ROSKAMM H
Citation: M. Buschmann et al., COMPARISON OF THE EFFECTS OF 2 DIFFERENT GALENICAL PREPARATIONS OF GLYCERYL TRINITRATE ON PULMONARY-ARTERY PRESSURE AND ON THE FINGER PULSECURVE, European Journal of Clinical Pharmacology, 44(5), 1993, pp. 451-456
Citation: D. Trenk et al., DETERMINATION OF THE INTERACTION OF 3S-HYDROXY-10,11-DIHYDROQUINIDINEON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN, Arzneimittel-Forschung, 43-2(8), 1993, pp. 836-841